Enanta Pharmaceuticals | ENTA - Sales Revenues

Stock Price
12.17
Daily Change
0.09 0.75%
Monthly
-15.54%
Yearly
107.68%
Q1 Forecast
12.13

Enanta Pharmaceuticals reported $16.96M in Sales Revenues for its fiscal quarter ending in December of 2024.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Amgen USD 9.9B 340M Dec/2025
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
Biogen USD 2.28B 250M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Halozyme Therapeutics USD 451.76M 97.76M Dec/2025
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Incyte USD 1.51B 140M Dec/2025
Insmed USD 263.8M 121.8M Dec/2025
Ionis Pharmaceuticals USD 203M 46M Dec/2025
J&J USD 24.6B 610M Dec/2025
Karyopharm Therapeutics USD 30.54M 8.24M Dec/2024
Ligand Pharmaceuticals USD 59.66M 55.8M Dec/2025
Merck USD 16.4B 880M Dec/2025
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Novartis USD 13.86B 50M Dec/2025
Novavax USD 147.14M 76.69M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025